In a pivotal virtual briefing, Minerva Neurosciences detailed its confirmatory Phase 3 trial design for roluperidone, a potential first-in-class therapy for the persistent and disabling negative symptoms of schizophrenia, with top-line results expected by late 2027.
Specialty chemicals leader Ashland reports a mixed Q1 FY2026, with resilient performance in Life Sciences and Personal Care offsetting continued softness in coatings and construction. The company revises its full-year EBITDA guidance, citing operational delays at a key facility and weather-related disruptions.
Tishman Speyer is reportedly in advanced negotiations to repurchase the Chrysler Building, a landmark left ownerless since last spring, but must first navigate the building's steep ground lease and significant deferred maintenance.
Analysts at Clear Street have increased their price target for Wave Life Sciences to $50, maintaining a Buy rating. The move follows GSK's decision to return rights to the alpha-1 antitrypsin deficiency candidate WVE-006, which the firm views favorably despite a muted market reaction.
Baron Discovery Fund's latest investor letter spotlights Exact Sciences (EXAS) as a key contributor, buoyed by strong market adoption of its cancer screening tests and favorable industry dynamics, despite the fund's broader quarterly underperformance.
Harvard Bioscience announces the closure of its Holliston, MA manufacturing facility, shifting operations to Minneapolis and Europe by 2027. The move, part of a strategic consolidation, is projected to yield $4 million in annual savings but raises concerns over local job losses and the state's business climate.
Johnson Controls International plc (JCI) is set to release its quarterly earnings before markets open Wednesday. Investors will scrutinize whether the building technology and solutions leader can maintain its recent outperformance amid a mixed landscape for commercial construction suppliers.
Azenta, Inc. is set to report its quarterly earnings before the market opens Wednesday. Analysts project stagnant year-over-year revenue, placing the spotlight on the company's ability to navigate a challenging market for life sciences tools and services.
Twist Bioscience's proprietary silicon-based DNA manufacturing platform is driving double-digit revenue growth and margin expansion, positioning the synthetic biology tools provider on a clear path to adjusted EBITDA breakeven by fiscal 2026.
A sophisticated, high-conviction options trade by a large investor signals strong confidence in Edwards Lifesciences' fundamentals, with a potential breakout eyed for early 2026 tied to regulatory milestones and sustained growth in its mitral valve business.
Despite recent stock pressure from its CRM platform migration, Veeva Systems' deep integration in life sciences workflows, robust financials, and expanding AI product suite present a compelling long-term investment case, analysts argue.
Gilead Sciences, the biopharma giant known for its HIV treatments, is strategically pivoting to become a major player in cancer therapy. Through targeted licensing and a focus on precision oncology, the company aims to build a multi-billion dollar revenue stream by the end of the decade, reducing its reliance on mature franchises.
Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.
Amid a sluggish housing sector, Installed Building Products (IBP) has demonstrated remarkable resilience, becoming a standout performer in Giverny Capital's portfolio. The insulation specialist's shares have surged over 50% in the past year, bucking broader market trends.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
